Amneal Announces Agreement with Zentiva to Divest Creo Pharma

Amneal Pharmaceuticals announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the company’s commercial operations in the United Kingdom.

“We believe that the value created by our commercial operations in the UK will be better maximized by Zentiva, which will gain additional products and enhanced competitive market share position as a result of this transaction,” said Rob Stewart, President and CEO of Amneal. “This transaction will permit Amneal to concentrate management time and resources to support our continued focus on strengthening our growing position in the U.S. market.”